Paediatric eosinophilic oesophagitis in New Zealand: A 3-year prospective study.
allergy
eosinophilic oesophagitis
gastroenterology
immunology
paediatrics
Journal
Journal of paediatrics and child health
ISSN: 1440-1754
Titre abrégé: J Paediatr Child Health
Pays: Australia
ID NLM: 9005421
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
19
10
2019
revised:
23
06
2020
accepted:
27
08
2020
pubmed:
13
9
2020
medline:
15
5
2021
entrez:
12
9
2020
Statut:
ppublish
Résumé
Eosinophilic oesophagitis (EoE) is a rare, chronic, relapsing immune/antigen-mediated disease characterised by symptoms of oesophageal dysfunction, with a paucity of data among New Zealand (NZ) children. This 3-year prospective study aimed to characterise EoE diagnosed nationally and to describe initial treatment strategies adopted. Information on new diagnoses of paediatric EoE was obtained via the New Zealand Paediatric Surveillance Unit, through monthly questionnaires. From February 2014 to January 2017, 73 new cases (74% male) of EoE were reported, including 74% NZ European, 10% Asian, 7% Māori, 5% Middle-Eastern and 3% Pacific peoples. Median age of symptom onset was 4 years; dysphagia (48%) was the most common, followed by vomiting/regurgitation (40%), food impaction (19%) and epigastric pain (16%). A co-morbid history of other allergic conditions was present in 62% of patients, and 41% had a first degree relative with atopy. Seventy-nine percent of patients had abnormal endoscopic findings, most commonly linear furrows and white plaques; none had strictures. Median eosinophil count per high-powered field was 40 and 50 in the mid and distal oesophagus, respectively. Fifty-four percent of patients were initially managed with dietary manipulation alone (four required elemental feeds, five nasogastric tubes). Fifty-four percent of patients were treated with swallowed corticosteroids and 7% with prednisone. One patient was also treated with a leukotriene receptor antagonist. This first prospective study on paediatric patients with EoE in NZ finds similar demographics and disease characteristics as in other populations despite our unique ethnic population. Long-term prospective observational data should significantly improve our knowledge of this rare condition.
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
234-238Informations de copyright
© 2020 Paediatrics and Child Health Division (The Royal Australasian College of Physicians).
Références
Papadopoulou A, Koletzko S, Heuschkel R et al. Management guidelines of eosinophilic esophagitis in childhood. J. Pediatr. Gastroenterol. Nutr. 2014; 58: 107-18.
Preece K, Blincoe A, Grangaard E et al. Paediatric non-IgE mediated food allergy: Guide for practitioners. N. Z. Med. J. 2016; 129: 78-88.
Raheem M, Leach ST, Day AS, Lemberg DA. The pathophysiology of eosinophilic esophagitis. Front. Pediatr. 2014; 2: 41.
Dellon ES, Hirano I. Epidemiology and natural history of eosinophilic esophagitis. Gastroenterology 2018; 154: 319-32.
Moawad FJ. Eosinophilic esophagitis: Incidence and prevalence. Gastrointest. Endosc. Clin. N. Am. 2018; 28: 15-25.
Navarro P, Arias Á, Arias-González L, Laserna-Mendieta EJ, Ruiz-Ponce M, Lucendo AJ. Systematic review with meta-analysis: The growing incidence and prevalence of eosinophilic oesophagitis in children and adults in population-based studies. Aliment. Pharmacol. Ther. 2019; 49: 1116-25.
Philpott H, Kweh B, Thien F. Eosinophilic esophagitis: Current understanding and evolving concepts. Asia Pac. Allergy 2017; 7: 3-9.
Weerasekera K, Sim D, Coughlan F, Inns S. Eosinophilic esophagitis incidence in New Zealand: High but not increasing. Clin. Exp. Gastroenterol. 2019; 12: 367.
Grenier D, Elliott EJ, Zurynski Y et al. Beyond counting cases: Public health impacts of national Paediatric Surveillance Units. Arch. Dis. Child. 2007; 92: 527-33.
Cherian S, Smith NM, Forbes DA. Rapidly increasing prevalence of eosinophilic oesophagitis in Western Australia. Arch. Dis. Child. 2006; 91: 1000-4.
Hruz P, Straumann A, Bussmann C et al. Escalating incidence of eosinophilic esophagitis: A 20-year prospective, population-based study in Olten County, Switzerland. J. Allergy Clin. Immunol. 2011; 128: 1349-50.
Philpott H, Sharma A, Rosenbaum J et al. Rapid increase in the prevalence of eosinophilic esophagitis among Australasian children: A decade of experience from six capital cities. J. Gastroenterol. Hepatol. 2019; 34: 203.
Lack G. Update on risk factors for food allergy. J. Allergy Clin. Immunol. 2012; 129: 1187-97.
Statistics New Zealand. Census QuickStats About Culture and Identity. Statistics New Zealand; 2013. Available from: http://archive.stats.govt.nz/Census/2013-census/profile-and-summary-reports/quickstats-culture-identity/ethnic-groups-NZ.aspx#gsc.tab=0
Papadopoulou A, Dias JA. Eosinophilic esophagitis: An emerging disease in childhood - review of diagnostic and management strategies. Front. Pediatr. 2014; 2: 129.
Gupta SK, Peters-Golden M, Fitzgerald JF et al. Cysteinyl leukotriene levels in esophageal mucosal biopsies of children with eosinophilic inflammation: Are they all the same? Am. J. Gastroenterol. 2006; 101: 1125-8.
Lucendo AJ, de Rezende LC, Jiménez-Contreras S et al. Montelukast was inefficient in maintaining steroid-induced remission in adult eosinophilic esophagitis. Dig. Dis. Sci. 2011; 56: 3551-8.
'Netzer P, Gschossmann JM, Straumann A, Sendensky A, Weimann R, Schoepfer AM. Corticosteroid-dependent eosinophilic oesophagitis: Azathioprine and 6-mercaptopurine can induce and maintain long-term remission. Eur. J. Gastroenterol. Hepatol. 2007; 19: 865-9.
Straumann A, Bussmann C, Conus S, Beglinger C, Simon HU. Anti-TNF-alpha (infliximab) therapy for severe adult eosinophilic esophagitis. J. Allergy Clin. Immunol. 2008; 122: 425-7.
Rocha R, Vitor AB, Trindade E et al. Omalizumab in the treatment of eosinophilic esophagitis and food allergy. Eur. J. Pediatr. 2011; 170: 1471-4.
Spergel JM, Rothernberg ME, Collins MH et al. Reslizumab in children and adolescents with eosinophilic esophagitis: Results of a double-blind, randomized, placebo-controlled trial. J. Allergy Clin. Immunol. 2012; 129: 456-63.
Dranove JE, Horn DS, Davis MA, Kernek KM, Gupta SK. Predictors of response to proton pump inhibitor therapy among children with significant esophageal eosinophilia. J. Pediatr. 2009; 154: 96-100.
Clark ST, Brothers S, Evans HM et al. Eosinophilic Oesophagitis - Audit of practice since initiation of Joint Gastroenterology and Immunology ClinicESPGHAN 52nd Annual Meeting Abstracts. J. Pediatr. Gastroenterol. Nutr. 2019; 68(S1): 303.
Menard-Katcher P, Marks KL, Liacouras CA, Spergel JM, Yang YX, Falk GW. The natural history of eosinophilic oesophagitis in the transition from childhood to adulthood. Aliment. Pharmacol. Ther. 2013; 37: 114-21.